AR-701
COVID-19
PreclinicalActive
Key Facts
About Aridis Pharmaceuticals
Aridis Pharmaceuticals is a US-based biotech focused on developing first-in-class anti-infectives, primarily monoclonal antibodies, for serious respiratory infections. The company's core technology identifies potent human mAbs from convalescent patients, creating therapies with mechanisms distinct from traditional antibiotics. Its most advanced assets are AR-301 (Phase 3) for ventilator-associated pneumonia and AR-501 (Phase 2a) for cystic fibrosis, positioning it in the high-need antimicrobial resistance (AMR) space. The company is publicly traded but currently limited to trading on the OTC Expert Market.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |